Available Technology

N6, A Novel, Broad, Highly Potent HIV-specific Antibody

This is a new antibody coming out of NIAID’s intramural program. N6 has evolved a unique mode of binding that depends less on a variable area of the HIV envelope known as the V5 region and focuses more on conserved regions, which change relatively little among HIV strains. This allows N6 to tolerate changes in the HIV envelope, including the attachment of sugars in the V5 region, a major mechanism by which HIV develops resistance to other VRC01-class antibodies. N6 was shown in pre-clinical studies to neutralize 98 percent of HIV isolates tested. The studies also demonstrate that N6 neutralizes 80 percent of HIV isolates which were resistant to other antibodies of the same class, and does so very potently. Its breadth and potency makes N6 a highly desirable candidate for development in therapeutic or prophylactic strategies.
Benefits: 
Neutralized 98 percent of HIV isolates tested -Neutralized 80 percent of HIV isolates which were resistant to other antibodies of the same class, and does so very potently
applications: 
Inventors: 
Peter Kwong
Patent Number: 
15/559,791
Internal Laboratory Ref #: 
E-131-2015/0
Share to Facebook Share to Twitter Share to Google Plus Share to Linkedin